

May 18-20, 2026 | Boston, MA

www.tcr-therapies-summit.com

ENJOY \$1,000 SAVINGS
WHEN YOU REGISTER
BEFORE FRIDAY,
FEBRUARY 27



7th Annual

TCR-Based Therapies Summit

Transforming T-Cell Receptor Cell & Biologic Approaches

Leveraging Novel Targets, Advanced Engineering & Clinical Strategies to Expand Patient Populations for In-Market Success of TCR-Based Cell & Biologic Therapies

Expert Speakers Include:



Cedrik Britten
Chief Medical Officer
Immatics



Joseph Dukes
Chief Scientific
Officer
Enara Bio



Luise Weigand
Chief Scientific
Officer
Zelluna
Immunotherapy



Annelise Vuidepot
Chief Technical
Officer
Immunocore



David DiLillo
Senior Director,
Immuno-Oncology
Regeneron
Pharmaceuticals



Cheng Liu
President & Chief
Executive Officer
Eureka Therapeutics

Proud to Partner With:



+1 617 455 4188 @ info@hansonwade.com

www.tcr-therapies-summit.com Cell & Gene Therapy Event Series



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Introducing the Only Meeting Bringing You Face-to-Face with TCR Industry Leaders

7th Annual
TCR-Based Therapies
Summit
May 18-20, 2026 | Boston, MA

TCR-based therapies are proving their value by delivering success in oncology, whilst also paving the way for new therapeutic frontiers beyond cancer. Even with this progress, the **high cost of goods**, **narrow patient populations** and **variable response rates** continue to limit scalability and investment. The next wave of innovation must provide new platforms, optimized formats, and smarter trial strategies that redefine potency, durability, and long-term commercial viability.

To support this pivotal moment, the **7th TCR-Based Therapies Summit** returns as the definitive forum uniting the close-knit TCR community to collaborate in overcoming critical challenges. Hear directly from industry veterans at **Immatics**, **Immunocore**, **Regeneron**, **Anocca**, **Enara Bio**, and **Zelluna Immunotherapy** driving both cell and biologic-based approaches to build robust, scalable, and clinically impactful treatments.

Showcasing how novel target discovery, next-generation engineering, and innovative manufacturing are transforming pipelines and accelerating progress, while **protecting long-term ROI**, this is the must-attend forum for TCR leaders. Benchmark your work against real-world strategies, explore cutting-edge technologies, and gain the strategic insights needed to make informed decisions that will future-proof your TCR-based therapies.

Do not miss the only meeting where TCR innovation takes the limelight.

Leave equipped with the actionable takeaways and real-world examples to implement resilient development plans, streamline production workflows, and drive transformative therapies to more patients.

What Your Peers Have Said

“The conference was the perfect size. I was able to have meaningful conversations with a range of people. The attendees were also very friendly, and I appreciated how much camaraderie was encouraged”

Senior Scientist, Aethon Therapeutics, 2025 Attendee

“The program was well organized and offered a good variety of talks, all focused on TCR”

Vice President & Manager, Research & Development, Pan Cancer T, 2025 Speaker

Key Benefits of Attending

			
Advance More Efficacious Therapies Through Improved Target Selection & TCR Engineering	Achieve More Durable Responses by Overcoming Tumor Escape & Resistance	Strengthen Safety by Optimizing Affinity, Specificity, & Dosing Decisions	Optimize Commercial Viability Through Smarter Patient Selection Strategy, Design & Manufacturing
Gain new perspectives into how both cell-based and biologic TCR approaches are being optimized to maximize therapeutic potential, through clinical updates in PRAME positive cancers and emerging work on TCR mimic antibodies	From multi-target strategies designed to limit tumor escape, to clinical insights on persistence and dual CD4/CD8 activation, spotlight concrete, durability-focused approaches. Walk away with a sharper insight of how long-term response considerations are being embedded into early engineering decisions	Hear industry-led intel into how developers are minimizing off-target risk without compromising potency and how they are using advanced screening and translational tools to guide smarter, safer development decisions	Join critical discussions on personalized versus shared strategies and innovative manufacturing approaches, to unpack how TCR developers are navigating cost and access constraints. Upskill your teams with the practical frameworks to align innovation with commercial viability

What You Can Look Forward to in 2026

7th Annual
TCR-Based Therapies
Summit
May 18-20, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Standout Sessions Not to Miss



Delivering Transformational Benefit with TCR-Based Therapies for PRAME Positive Cancers

Cedrik Britten, Chief Medical Officer, Immatics

1



Accelerating Affinity Maturation with AI & Machine Learning to Shorten Development Timelines & Improve Precision

Tao Wang, Associate Professor, Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center

2



Applying TCR Mimic Antibodies in T-Cell Therapy to Achieve Durable & Persistent Clinical Responses

Cheng Liu, President & Chief Executive Officer, Eureka Therapeutics

3



Expanding Treatable Patient Populations with a Novel CD45 Target

Mollie Jurewicz, Director, TCR & Autoimmune Discovery, TScan Therapeutics

4



From Custom to On-Demand: Making TCR-Based Cell Therapies Commercially Scalable

Emilie Gauthy, Head, CMC, Zelluna Immunotherapy

5

New Companies for 2026



Showcase Your Scientific Poster



Participate in our scientific poster session to contribute to the conversation, spotlight your breakthrough discoveries and share your cutting-edge research with the full TCR-based therapy development community.

Register your place and submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

3

+1 617 455 4188 @ info@hansonwade.com

www.tcr-therapies-summit.com Cell & Gene Therapy Event Series



Your Expert Speakers

7th Annual
TCR-Based Therapies
Summit
May 18-20, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

C-Suite Strategic Leaders



Stefan Scherer
Chief Executive Officer &
President
3T Biosciences



Reagan Jarvis
Chief Executive Officer &
Co-Founder
Anocca



Joseph Dukes
Chief Scientific Officer
Enara Bio



Cheng Liu
President & Chief
Executive Officer
Eureka Therapeutics



Cedrik Britten
Chief Medical Officer
Immatics



Annelise Vuidepot
Chief Technology Officer
Immunocore



Zhen Su
Chief Executive Officer &
Director
Marengo Therapeutics



Ke Liu
Chief Development Officer
Marengo Therapeutics



Rachel Abbott
Chief Executive Officer
Pan Cancer T



Peggy Sotiropoulou
Chief Scientific Officer
T-knife Therapeutics



Luise Weigand
Chief Scientific Officer
Zelluna Immunotherapy

Biopharma Technical Experts



Lorenzo Maso
Principal Scientist
Aethon Therapeutics



Qi Zhao
Principal Scientist
BioNTech



Serena Stadler
Senior Scientist
Captain T Cell



Ricard Masia
Senior Director,
Translational Medicine
Crossbow Therapeutics



Gene Uenishi
Associate Director,
Discovery
GentiBio



David DiLillo
Senior Director,
Immuno-Oncology
**Regeneron
Pharmaceuticals**



Sarah Leonard
Vice President, Preclinical
Development, TCR-Based
Therapeutics
T-Cypher Bio



Mollie Jurewicz
Director, TCR &
Autoimmune Discovery
TScan Therapeutics



Emilie Gauthy
Head, CMC
Zelluna Immunotherapy

Academic Pioneers



Cassian Yee
Director, T-Cell-Based
Therapies (ProTCT),
Division of Cancer
Medicine
**The University of Texas
MD Anderson Cancer
Center**



Tao Wang
Associate Professor,
Bioinformatics &
Computational Biology
**The University of Texas
MD Anderson Cancer
Center**

Pre-Conference Workshop Day

Monday, May 18

Registration & Coffee 8.30

Workshop A 9.30

Discovering the Next-Generation of TCR Targets to Expand Patient Reach & Improve Therapeutic Impact

Uncover how the field is moving beyond familiar targets like MAGE-A4 and PRAME to identify novel antigens that expand patient reach and improve clinical outcomes. This workshop dives into cutting-edge technologies, non-canonical targets, and next-generation engineering strategies that are redefining TCR therapy. Gain practical insights into building robust discovery pipelines, validating tumor specificity, and designing therapies that stand out in a competitive landscape.

Join this workshop to:

- Explore emerging target spaces including non-canonical antigens, alternative HLA molecules, and strategies to increase prevalence and density for broader patient access
- Find new ways to expedite the target validation process using a broad range of tools
- Apply computational tools to discover and validate targets faster and more accurately
- Design next-generation TCR formats to maximize efficacy and durability of response

Workshop Leaders



Joseph Dukes
Chief Scientific Officer
Enara Bio



Cassian Yee
Director, T-Cell-Based
Therapies (ProTCT),
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer
Center



Sarah Leonard
Vice President, Preclinical
Development, TCR-Based
Therapeutics
T-Cypher Bio

Lunch Break & Networking 12.30

Workshop B 1.30

Leveraging Novel Engineering Strategies to Overcome Tumor Escape & Amplify Potency

As solid tumors continue to present challenges such as heterogeneity, immune evasion, and poor durability, the field is increasingly turning to advanced engineering solutions to redefine therapeutic potential. This workshop will explore cutting-edge approaches, from multi-antigen targeting strategies to next-generation TCR formats designed to amplify potency, mitigate tumor escape, and deliver deeper more durable responses that improve both patient outcomes and commercial viability.

Join this workshop to:

- Develop multi-target strategies that reduce tumor escape and expand therapeutic reach across diverse solid tumor indications
- Explore the engineering of next-generation constructs that maximize potency while maintaining safety and an optimal patient experience
- Establish best practices for monitoring cell persistence using advanced bioanalytical assays
- Assess half-life profiles to overcome dosing challenges while minimizing patient burden

Workshop Leaders



Peggy Sotiropoulou
Chief Scientific
Officer
T-knife
Therapeutics



Serena Stadler
Senior Scientist
Captain T Cell

End of Pre-Conference Workshop Day 4.30

Conference Day One

Tuesday, May 19

7th Annual
TCR-Based Therapies
Summit
May 18-20, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Registration & Coffee



Cassian Yee
Director, T-Cell-Based
Therapies (ProTCT),
Division of Cancer
Medicine
**The University of
Texas MD Anderson
Cancer Center**

8.50 Chair's Opening Remarks

Using Clinical Learnings to Guide Next-Generation TCR Innovation & Accelerate Progress

9.00 C-Level Fireside Chat: Reflecting on Lessons from TCR Therapies to Drive Next-Generation Strategies

- Identifying pivotal learnings that can sharpen development strategies and accelerate stronger clinical outcomes
- Framing actionable insights that translate early proof-of-concept gains into durable, real-world clinical impact
- Exploring critical knowledge gaps and defining high-value priorities that can shape the next-generation of TCR innovations



Annelise Vuidepot
Chief Technology Officer
Immunocore



Cedrik Britten
Chief Medical Officer
Immatics



Luise Weigand
Chief Scientific Officer
Zelluna Immunotherapy



Peggy Sotiropoulou
Chief Scientific Officer
T-knife Therapeutics



Reagan Jarvis
Chief Executive Officer &
Co-Founder
Anocca



Annelise Vuidepot
Chief Technology
Officer
Immunocore
New Data

10.00 Expanding the Potential of TCR-Based T-Cell Engagers into Infectious Diseases

- Sharing early clinical data on TCR-based bispecific molecules developed to treat HBV and HIV
- Analyzing the pharmacokinetics and pharmacodynamics associated with this mechanism of action
- Highlighting the differences from oncology that emerge due to a lack of suppressive tumor microenvironment



Cedrik Britten
Chief Medical Officer
Immatics

10.30 Delivering Transformational Benefit with TCR-Based Therapies for PRAME Positive Cancers

- Demonstrating first-generation autologous TCR therapy Anzu-Cel achieving 50-60% durable responses in melanoma
- Advancing second-generation efficacy enhanced PRAME TCRs into ovarian and endometrial cancers and the prospect of tissue agnostic expansion
- Bispecific TCR approaches to maximize clinical impact while addressing development and scalability challenges



11.00 Morning Break & Speed Networking

Integrating Machine Learning & Advanced Screening for Safer Affinity Maturation



Tao Wang
Associate Professor,
Bioinformatics &
Computational Biology
**The University of
Texas MD Anderson
Cancer Center**
New Data

12.00 Accelerating Affinity Maturation with AI & Machine Learning to Shorten Development Timelines & Improve Precision

- Exploring how AI-driven design can shorten traditional affinity maturation cycles and reduce experimental burden
- Questioning whether current AI tools can reliably predict TCR-peptide-HLA interactions
- Defining what success looks like for AI in TCR engineering and the data needed to prove clinical relevance

Conference Day One

Tuesday, May 19

7th Annual
TCR-Based Therapies Summit
May 18-20, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



12.30 Building Next-Generation TCR-TCEs Through High-Titer Expression & Optimized Affinity Maturation

- Achieving high-titer CHO production of soluble TCRs and TCR-TCEs using the WuXian Transient™ expression system
- Optimizing TCR affinity maturation from phage libraries to routinely improve KD by ~10,000-fold (from 10-100 μM)
- Integrating high-throughput expression and affinity maturation to efficiently generate building blocks for next-generation TCR-TCE therapeutics



13.00 Lunch Break & Networking

Driving Innovation with TCR Mimic Antibodies to Expand Therapeutic Possibilities



David DiLillo
Senior Director,
Immuno-Oncology

**Regeneron
Pharmaceuticals**

New Data

14.00 Next-Generation HLA/Peptide-Targeted Therapies: Lessons Learned from Comparing TCR-T Versus TCR Mimetic CAR-T

- State-of-the-art techniques for discovering tumor-specific HLA/peptide targets and technologies for generating TCRs and TCR mimetic antibodies
- Directly compare and contrast TCR-T versus TCR mimetic CAR-T cells *in vitro* and *in vivo*
- Engineering T-cells and combinations with biologics for optimal deployment of HLA/peptide-targeted therapies in the clinic



Cheng Liu
President & Chief
Executive Officer

Eureka Therapeutics

New Data

14.30 Applying TCR Mimic Antibodies in T-Cell Therapy to Achieve Durable & Persistent Clinical Responses

- Sharing developments in an ongoing phase 1 trial and key learnings from the clinic
- Explaining how TCR mimic armed T-cell therapy enables dual activation of CD4 and CD8 T-cells
- Discuss why CD4 engagement is critical for long-term efficacy



15.00 Session Reserved for Alloy Therapeutics



15.30 Afternoon Break & Poster Session

Achieving Both Efficacy & Commercial Viability with New Innovations in TCR-Based Therapies



Reagan Jarvis
Chief Executive Officer
& Co-Founder

Anocca

16.30 Balancing Personalization & Scalability in Next-Generation TCR Therapies to Expand Patient Access

- Examining how personalization can sharpen therapeutic precision while introducing cost and complexity trade-offs critical for strategic planning
- Comparing personalized and shared TCR strategies to identify the optimal balance of precision, accessibility, and real-world patient reach
- Designing regulatory and manufacturing pathways that enable scalable, compliant use of personalized TCR therapies



Qi Zhao
Principal Scientist

BioNTech

17.00 Integrating Cutting-Edge Technologies, Including Multi-Omics & AI-Driven Data, to Advance Potent Personalized TCR-Based Therapies

- Personalized TCRs are both achievable and practical, offering great potential to broaden patient populations
- Enhanced TCR targetability and potency through the integration of multi-omics data
- Leveraging AI to predict TCR-pMHC folding structures, guiding TCR specificity and enhancing target diversity

17.30 End of Conference Day One



+1 617 455 4188

@ info@hansonwade.com

www.tcr-therapies-summit.com

Cell & Gene Therapy Event Series



Conference Day Two

Wednesday, May 20

7th Annual
TCR-Based Therapies
Summit
May 18-20, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Registration & Coffee



Zhen Su
Chief Executive Officer
& Director
Marengo
Therapeutics

8.50 Chair's Opening Remarks

Comparing New TCR-Based Strategies to Expand Targets & Overcome Resistance



Ricard Masia
Senior Director,
Translational Medicine
Crossbow
Therapeutics

9.00 **Preclinical Characterization of CBX-663, a First-in-Class TCR Mimetic T-Cell Engager Targeting TERT for Solid & Hematologic Malignancies**

- Rationale for Crossbow Therapeutics' approach to TERT targeting and for CBX-663 design
- *In vitro* binding and *in vitro* potency against cancer cell lines, demonstrating superior potency of bivalent vs. monovalent format (2+1 vs 1+1)
- *In vivo* efficacy in mouse CDX models of AML and NSCLC, and *in vitro* and *in vivo* safety with focus on bone marrow progenitor cells



Ke Liu
Chief Development
Officer
Marengo Therapeutics
[New Data](#)

9.30 **Activating T-Cells Through Novel TCR-Based Platforms to Overcome Resistance in Solid Tumors**

- Introducing the first-in-class STAR platform that selectively activates T-cells via the variable beta chain
- Demonstrating feasibility and safety of this novel mechanism with encouraging preliminary clinical data
- Achieving pan-tumor activity across seven solid tumor types, and HLA-agnostic TCR activation to broaden patient access and redefine therapeutic strategies



10.00 Session Reserved for Adimab



10.30 Morning Break & Networking

Leveraging Novel Techniques to Exploit Resistance Mechanisms & Broaden Patient Impact



Lorenzo Maso
Principal Scientist
Aethon Therapeutics
[New Data](#)

11.00 **Expanding Therapeutic Possibilities Pursuing pMHC Targets Beyond Convention**

- Antigen-guided TCE development
- Targeting haptenated peptides as a way of breaking HLA restriction
- Exploiting resistance mechanisms to cancer treatments that unlock new targets for immunotherapies



Mollie Jurewicz
Director, TCR &
Autoimmune Discovery
TScan Therapeutics

11.30 **Expanding Treatable Patient Populations with a Novel CD45 Target**

- Understanding the impact that broader patient impact will have on the haem space
- Outlining the lead selection process to identify a target restricted to the hematopoietic system, ensuring safe and efficacious therapies
- Presenting preclinical data from the TCR discovery process



Miltenyi Biotec

12.00 Session Reserved for Miltenyi Biotec



12.30 Lunch Break & Networking



+1 617 455 4188

@ info@hansonwade.com

www.tcr-therapies-summit.com

Cell & Gene Therapy Event Series



Conference Day Two

Wednesday, May 20

Streamlining Manufacturing to Improve Cost Efficiency & Accelerating Progress into the Clinic

13.30 Bringing a Next-Generation Autologous TCR-T-Cell Therapy into the Clinic for Triple Negative Breast Cancer



Rachel Abbott
Chief Executive Officer
Pan Cancer T

- Introducing a first-in-class TCR engineered therapy against a novel target expressed in over 90 percent of triple negative breast cancer and melanoma patients
- Demonstrating how built in co-stimulatory domains within the TCR can enhance T-cell durability while maintaining a compact engineering payload relevant for future *in vivo* delivery
- Translating promising preclinical data into a cost-effective and scalable clinical manufacturing strategy to unlock cell therapy for hard-to-treat solid tumors

14.00 From Custom to On-Demand: Making TCR-Based Cell Therapies Commercially Scalable



Emilie Gauthy
Head, CMC
Zelluna Immunotherapy

New Data

- Changing the paradigm, from autologous to allogeneic, from single antigen to multiple activation mechanisms, from custom to on-demand
- Current opportunities and challenges of large-scale TCR-NK cells manufacturing
- Approaches to tackle cost-of-goods and increase patient access



14.30 Afternoon Break & Networking

Advancing TCR Therapies from Discovery to Clinical Translation & Commercial Success

15.30 Translating TCR-Based Cell Therapies into the Clinic



Gene Uenishi
Associate Director,
Discovery
GentiBio

- Enabling technologies for allogeneic TCR-engineered Treg therapies for autoimmune disease
- Safety considerations and risk-mitigation approaches for an allogeneic TCR therapies for autoimmune disease
- Regulatory strategy and IND-enabling experience for autologous TCR-based cell therapy programs

16.00 Guiding TCR Therapies from Discovery to Dosing Using End-to-End Platform Insights



Stefan Scherer
Chief Executive Officer
& President
3T Biosciences

- Conducting MABEL calculations and safety studies in organoids to guide dosing
- Characterizing clinical performance early to strengthen development decisions
- Leveraging the end-to-end benefits of a target discovery platform to derisk your product

16.30 End of the 7th TCR-Based Therapies Summit

“This meeting is very focused and informative, with a great format for networking and discussing challenges in the field”

Senior Vice President, Discovery, **Immunoscope**, 2024 Speaker

Our 2026 Partners

7th Annual
TCR-Based Therapies
Summit
May 18-20, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Expertise Partner Adimab

Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. We're committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.

www.adimab.com



Expertise Partner Alloy Therapeutics

Alloy Therapeutics accelerates the drug discovery process by providing access to best-in-class foundational drug discovery platforms, services, and company creation capabilities. Alloy Therapeutics has developed novel strains for fully human antibody discovery and created innovative technology to support a multitude of modalities that can help to quickly identify candidates. Leveraging our world class scientists, Alloy Therapeutics' platforms and services enables you to build a more robust antibody-based therapeutic pipeline.

www.alloytx.com



Miltenyi Biotec

Expertise Partner Miltenyi Biotec

Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, transforming scientific discoveries into practical treatments for personalized medicine. With over 35 years of expertise, it supports biomedical discoveries and translates them into clinical applications, enhancing patient access to new therapies. Miltenyi Biotec focuses on offering integrated solutions for complex challenges in treating cancers, autoimmune diseases, and inherited disorders. Its Miltenyi Bioindustry division provides expert guidance to therapy developers efficiently from process development to commercialization. Headquartered in Bergisch Gladbach, it employs 4,900 people across 24 countries.

www.miltenyibiotec.com



Expertise Partner WuXi Biologics

WuXi Biologics is a leading contract research, development, and manufacturing organization (CRDMO), with the R represented by our premium-quality CRO services. Backed by drug development expertise, our modular solutions span every stage of biologics research, including antibody discovery, protein production and engineering, and *in vitro* and *in vivo* testing. With extensive experience across diverse modalities, such as monoclonal and bispecific antibodies, fusion proteins, TCRs, miniproteins, cytokines, and enzymes, we deliver innovative, customized services to seamlessly advance our clients' molecules from concept to CMC development.

www.wuxibiologics.com/cro-services

Get Involved



Kieran Crewe
Senior Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Our 2026 Partners

7th Annual
TCR-Based Therapies
Summit
May 18-20, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Event Partner Roslin Cell Therapies

RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the ground-breaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones. These include being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with the partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialization.

Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, Cell Banking and cGMP iPSC cell line development, gene editing, and differentiation.

With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. RoslinCT is a GHO Capital portfolio company.

www.roslinct.com

■ ■ As the only conference focusing on TCR-based therapeutics, the intimate meeting permitted for frequent discussions with other participants ■ ■

Head, Translational Medicine, **Engimmune Therapeutics**, 2025 Attendee

■ ■ It is great to have a very focused conference on TCRs and TCR mimics ■ ■

Senior Vice President, Chief Technology Officer & Head, Pipeline & Platform Research,
Immunocore, 2025 Speaker

Get Involved



Kieran Crewe
Senior Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partner With Us

7th Annual
TCR-Based Therapies
Summit
May 18-20, 2026 | Boston, MA

WELCOME

EXPERT
SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Dedicated Platform for Strengthening Existing Partnerships & Forging New Connections with TCR Decision-Makers

The **7th TCR-Based Therapies Summit** returns at a pivotal moment for the TCR community. As the field matures, developers know success does not stop at approval; they need expert partners to overcome mission-critical challenges in manufacturing, research, and commercial viability.

Our audience of biopharma decision-makers are actively seeking solutions across TCR discovery and sequencing, HLA typing, immune screening, companion diagnostics, and preclinical model provision to deliver therapies that are safe, efficacious, durable, and deliver long-term ROI.

Offering you direct, frontline access to the companies leading the charge, this is your chance to position your organization as the trusted partner driving progress in TCR innovation.



Showcase your expertise to an audience tackling high-priority challenges in dedicated networking breaks



Build and nurture strategic relationships with leaders shaping the future direction of TCR therapies




Educate innovators on how your solutions accelerate development, de-risk pipelines and enhance market viability




Stay ahead of evolving trends to align your 2026 commercial strategy with the need of your ideal, target client

Seniority of Attendees



Type of Companies Attending



Statistics taken from the 6th TCR-Based Therapies Summit

Get Involved



Kieran Crewe
Senior Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

 www.tcr-therapies-summit.com/register/

 Tel: +1 617 455 4188

 Email: info@hansonwade.com



Unlock the full potential of TCR-based therapies by diving into the latest preclinical and clinical data that will set the benchmark for best-in-class treatments



Gain strategic insights from across the TCR field to design optimal therapeutics and streamline progression from discovery through to translation and clinical development



Engage in high-value networking and collaborative discussions at the only meeting dedicated exclusively to TCR cell and biologic-based therapies

Drug Developer Pricing*	Register by Friday, February 27	On The Door
Full Access Pass: Conference + Workshop Day	\$3,397 (Save \$1,000)	\$4,397
Conference Only	\$2,599 (Save \$500)	\$3,099

Academic & Not-For-Profit Pricing**	Register by Friday, February 27	On The Door
Full Access Pass: Conference + Workshop Day	\$2,797 (Save \$1,000)	\$3,797
Conference Only	\$2,199 (Save \$500)	\$2,699

Service & Solution Provider Pricing	Register by Friday, February 27	On The Door
Full Access Pass: Conference + Workshop Day	\$4,297 (Save \$1,000)	\$5,297
Conference Only	\$3,299 (Save \$500)	\$3,799

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for the academic and not-for-profit rate you must be either a full time academic or work for a not-for-profit organization. Please visit the website for full pricing options or email info@hansonwade.com


Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

The Colonnade Hotel
120 Huntington Avenue, Boston, Massachusetts, USA, 02116
For further information or assistance, please visit:
www.colonnadehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom